Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

Fig. 4

The subgroup of patients who had receive perioperative therapy with prior (neo) adjuvant anthracycline- and/or taxane-based regimens, the overall survival in the eribulin and non-eribulin groups (A), early-line eribulin group and non-eribulin group (B) and late-line eribulin group and non-eribulin group (C). OS: Overall survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us